Fecal microbiome

PreclinicalBiologic

FFondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

Fecal microbiome is one of 50 biologic programs targeting Immune Thrombocytopenia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Immune ThrombocytopeniaActive, not recruiting

Immune ThrombocytopeniaPreclinical

Active, not recruiting

Competition

Competitive Landscape

56 competitors in Immune Thrombocytopenia

#DrugCompanyPhaseTrials

Promacta

GSK

Approved

14 2

Rituxan

Roche

Approved

13 3

Decadron

AAspen Global Incorporated

Approved

21 4

Plaquenil

Jazz Pharmaceuticals

Approved

1 5

Oncovin

Eli Lilly

Approved

1 6

Rayos

RRoxane Laboratories

Approved

6 7

Imuran

LLegacy Health System

Approved

1 8

Vyvgart

Argenx

Phase 3

6 9

Doptelet

AAkarx

Phase 3

6 10

Wayrilz

GGenzyme, a Sanofi Company

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2035

Recruiting

Immune Thrombocytopenia

NCT05931718

Clinical

Trials by Indication[1]

Immune Thrombocytopenia1 trial

Prospective Evaluation of Diagnosis and Treatment of Patients With Autoimmune Cytopenias Including Autoimmune Hemolytic Anemia, Immune Thrombocytopenia, and Chronic Idiopathic/Autoimmune Neutropenia

Recruiting·FFondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico··NCT05931718·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Fecal microbiome. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fecal microbiome compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Fecal microbiome. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: FFondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

Fecal microbiome

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2035

Trials by Indication[1]

Immune Thrombocytopenia1 trial

References

Drug Info

Quick Facts

Related News